Citius Oncology, Inc. CTOR In Process Research And Development Initial Payments
In Process Research And Development Initial Payments at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept ctor:InProcessResearchAndDevelopmentInitialPayments.
The official record: Citius Oncology, Inc.’s 10-K, filed December 23, 2025, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s in process research and development initial payments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s in process research and development initial payments?
- Citius Oncology, Inc. (CTOR) reported in process research and development initial payments of $10M in Q3 2025.
- What does in process research and development initial payments mean?
- Represents the upfront cash consideration paid to acquire or license intellectual property or research assets that have not yet reached technological feasibility. These payments are critical for assessing the company's strategy for pipeline expansion and external innovation. High initial payments indicate a significant commitment to acquiring external R&D capabilities.